Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis

Expert Review of Vaccines

Volumn 17, Issue 5, 2018, Pages 435-443

  Lee, Jason K H ^a,b   Lam, Gary K L ^a,b   Shin, Thomas ^b,c   Kim, Jiyeon ^a,b   Krishnan, Anish ^a,b   Greenberg, David P ^d,e   Chit, Ayman ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Sanofi Pasteur   (Canada)

^c YORK UNIVERSITY   (Canada)

^d SANOFI PASTEUR   (France)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

death; effectiveness; efficacy; elderly; High dose influenza vaccine; hospitalization; influenza; meta analysis; seniors; systematic review

Indexed keywords

INFLUENZA VACCINE; VACCINE;

AGED; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CLINICAL OUTCOME; DEATH; DRUG DOSE COMPARISON; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; FLU LIKE SYNDROME; HOSPITAL ADMISSION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFORMATION RETRIEVAL; MEDICAL DECISION MAKING; META ANALYSIS; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; SYSTEMATIC REVIEW; AGE; COMPARATIVE STUDY; HOSPITALIZATION; PROCEDURES; SEASON; STATISTICS AND NUMERICAL DATA; VACCINATION;

AGE FACTORS; AGED; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PNEUMONIA; SEASONS; VACCINATION;

EID: 85047121916     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2018.1471989     Document Type: Article

References (41)

1. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333–1340.
2. Barker WH, Mullooly JP., Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med. 1982;142:85–89.
3. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza — United States, 1976–2007. MMWR Morb Mortal Wkly Rep. 2010;59:1057–1062.
4. Zheng B, Zhang Y, He H, et al. Rectification of age-associated deficiency in cytotoxic T cell response to influenza A virus by immunization with immune complexes. J Immunol. 2007;179:6153–6159.
5. Pv T, Rm J, Ga P., Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine. 2007;25:3066–3069.
6. Centers for Disease Control and Prevention. Washington (DC): Early release of selected estimates based on data from the 2014 National Health Interview Survey. CDC, 2015. cited 2018 Feb19. Available from: http://www.cdc.gov/nchs/data/nhis/earlyrelease/earlyrelease201506.pdf
7. Legrand J, Vergu E, Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine. 2006;24:6605–6611.
8. Smith JC, Snider DE, Pickering LK. Immunization policy development in the United States: the role of the Advisory Committee on Immunization Practices. Ann Intern Med. 2009 Jan 6;150(1):45–49.
9. Smith JC. The structure, role, and procedures of the US Advisory Committee on Immunization Practices (ACIP). Vaccine. 2010 Apr 19;28:A68–75.
10. CDC. New framework (GRADE) for development of evidence-based recommendations by the Advisory Committee on Immunization Practices. MMWR. 2012;61(18):327.
11. Domnich A, Arata L, Amicizia D, et al. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2016;35:513–520.
12. Wilkinson K, Wei Y, Szwajcer A, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis. Vaccine. 2017 May 15;35(21):2775–2780.
13. Transparent Reporting of Systematic Reviews and Meta-Analyses. Ottawa Hospital Research Institute and University of Oxford. cited 2018 Feb19.Available from: http://prisma-statement.org/Default.aspx
14. Downs SH, Black H. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–384.
15. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48.
16. Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49:1–5.
17. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315:629–634.
18. Random-effects (DerSimonian and Laird) method for meta-analysis. Cochrane Handbook.cited 2018 Feb19. Available from: http://handbook.cochrane.org/chapter_9/9_4_3_1_random_effects_dersimonian_and_laird_method_for.htm
19. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15:293–300.
20. Shay DK, Chillarige Y, Kelman J, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012–2013 and 2013–2014. J Infect Dis. 2017;215:510–517.
21. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–645.
22. DiazGranados CA, Dunning AJ, Jordanov E, et al. High-dose trivalent influenza vaccine compared to standard-dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009–2010 season. Vaccine. 2013;31:861–866.
23. Young-Xu Y, Van Aalst R, Mahmud SM, et al. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among Veterans Health Administration patients. J Infect Dis. 2018 Feb;14. [Epub ahead of print]
24. DiazGranados CA, Robertson CA, Talbot HK, et al. Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine. 2015;33:4988–4993.
25. Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med. 2017;5:738–746.
26. Gravenstein S, Davidson HE, Han LF, et al. Feasibility of a cluster-randomized influenza vaccination trial in US nursing homes: lessons learned. Hum Vaccin Immunother. 2017;1:1–8.
27. Richardson DM, Medvedeva EL, Roberts CB, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans. Clin Infect Dis. 2015;61:171–176.
28. National Advisory Committee on Immunization (NACI). A Review of the Literature of High Dose Seasonal Influenza Vaccine for Adults 65 Years and Older.cited 2018 Feb19. Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/a-review-literature-high-dose-seasonal-influenza-vaccine-adults-65-years-older.html.
29. National Advisory Committee on Immunization (NACI). Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2017–2018.cited 2018 Feb19. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2017-2018.html
30. Widdowson MA, Bresee JS. High-dose influenza vaccine in nursing home residents: not to be sneezed at. Lancet Respir Med. 2017;5:674–676.
31. Halasa NB, Savani BN, Asokan I, et al. Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplantation patients. Biol Blood Marrow Transplant. 2016;22:528–535.
32. GiaQuinta S, Michaels MG, McCullers JA, et al. Randomized, double-blind comparison of standard-dose vs high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients. Pediatr Transplant. 2015;19:219–228.
33. Jamshed S, Walsh EE, Dimitroff LJ, et al. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial. Vaccine. 2016;34:630–635.
34. McManus M, Frangoul H, McCullers JA, et al. Safety of high dose trivalent inactivated influenza vaccine in pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:815–820.
35. McKittrick N, Frank I, Jacobson JM, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med. 2013;158:19–26.
36. Natori Y, Shiotsuka M, Slomovic J, et al. A double blind randomized trial of high dose vs. standard dose influenza vaccine in adult solid organ transplant recipients. Clin Infect Dis. 2017 Dec;14. [Epub ahead of print]
37. DiazGranados CA, Dunning AJ, Robertson CA, et al. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine. 2015 Aug 26;33(36):4565–4571.
38. Falsey AR, McElhaney JE. Influenza burden in frail elderly. Lancet Respir Med. 2018;6:e2.
39. US Centers for disease control and prevention. flu view: national and regional level outpatient illness and viral surveillance. cited 2018 Mar31. Accessed from: http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html
40. Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. New England J Med. 2017 Jun 22;376(25):2427–2436.
41. McElhaney JE, Beran J, Devaster JM, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013 Jun 1;13(6):485–496.